A phase I study for evaluation of the safety, tolerability and pharmacokinetics of dose-escalation ACT001 in patients with advanced glioblastoma
Latest Information Update: 10 Jul 2021
At a glance
- Drugs ACT 001 (Primary)
- Indications Astrocytoma; Choroid neoplasms; Ependymoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 08 Jun 2021 Results (n=16) assessing the Pharmacokinetics, adverse events, therapeutic efficacy of ACT001 in patients with advanced glioma, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 01 Dec 2017 New trial record